NCT00931528已完成3 期
A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 242
- 试验地点
- 192
- 主要终点
- Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)
研究概览
简要总结
RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction.
PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.
详细描述
OBJECTIVES:
Primary
- To determine whether tadalafil maintains spontaneous (off-drug) erectile function, as measured by the International Index of Erectile Function (IIEF) as compared to placebo at weeks 28-30 after initiation of radiotherapy in patients with prostate cancer.
Secondary
- Determine the difference in spontaneous (off-drug) erectile function between tadalafil and placebo at 1 and 2 years.
- Determine the difference in overall sexual function as measured by the IIEF between tadalafil and placebo at weeks 28-30 and at 1 and 2 years.
- Determine differences in patient and partner overall sexual satisfaction as measured by the Sexual Adjustment Questionnaire (SAQ) between tadalafil and placebo at weeks 28-30 and at 1 and 2 years.
- Determine differences in patient and partner marital adjustment as measured by Locke's Marital Adjustment Test (LMAT) between tadalafil and placebo at weeks 28-30 and at 1 and 2 years.
- Determine associations between patient and partner overall sexual satisfaction as measured by SAQ and patient and partner marital adjustment as measured by LMAT at weeks 28-30 and at 1 and 2 years.
- Determine patient-related factors (i.e., age, pretreatment sexual response, tobacco use, and comorbidities) that may predict response to tadalafil therapy at weeks 28-30 and at 1 and 2 years.
- Determine the difference in adverse events between tadalafil and placebo as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Clinical stage T1b-T2b (AJCC, 6th ed.) adenocarcinoma of the prostate within 6 months of registration
- •Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), nodal sampling, or dissection within 3 months prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm. Lymph node assessment is optional, and at investigator discretion, for patients with Gleason Score <
- •No evidence of bone metastases (M0) on bone scan within 3 months prior to registration. Equivocal bone scan findings are allowed if plain films are negative for metastasis. Bone metastases assessment is optional, and at investigator discretion, for patients with Gleason Score <
- •Baseline serum prostatic specific antigen (PSA) value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 3 months prior to registration.
- •4.1 Any of the following combinations of factors (NOTE: tumor found in 1 or both lobes on biopsy, but not palpable, will not alter T stage):
- •T1b-T2b disease, Gleason Score <7 and serum total PSA that is <20 ng/ml or
- •T1b-T2b disease, Gleason Score ≥7 and PSA that is <15 ng/ml
- •Serum total testosterone level prior to the initiation of radiation therapy (RT) within normal range according to institutional guidelines
- •Zubrod Performance Status 0 or 1 (Appendix III)
- •Age ≥ 18 years
- •Treatment that will consist of either external beam RT alone to the prostate ± seminal vesicles only at a dose between 75 Gy and 79.2 Gy or brachytherapy alone (NOTE: treatment with combined external RT and brachytherapy excludes patient participation)
- •Pretreatment (before starting prostate cancer treatment) erectile function as measured by IIEF Question 1, "How often were you able to get an erection during sexual activity?" - with responses of:
- •"sometimes (about half the time)" [response 3] or
- •"most times (much more than half the time)" [response 4] or
- •"almost always/always" [response 5]
- •History of prior tadalafil use: Document usual dosage per sexual encounter, date of last dose, and patient's response (No; Yes-Unsatisfactory Response; Yes-Satisfactory Response). Regardless of past experience, the patient is eligible if he agrees to adhere to protocol and take only tadalafil or placebo prescribed on study.
- •Although patients with partners are targeted for recruitment, patients without partners or without partners willing to participate are eligible. Patients (and spouses/partners, if willing to participate) must be able to provide study-specific informed consent.
排除标准
- •The patient's participation in another medical research study that involves the treatment of ED
- •Previous or concomitant invasive cancer (American Joint Committee on Cancer [AJCC] Stage >0), other than localized basal cell or squamous cell skin carcinoma (AJCC Stage 0-II), or a hematological malignancy (e.g., leukemia, lymphoma, myeloma) unless continually disease free for at least 5 years
- •History of myocardial infarction within the last year
- •Heart failure in the last 6 months
- •Uncontrolled arrhythmias, hypotension (<90/50mm Hg), or uncontrolled hypertension (>170/100 mm Hg)
- •Stroke within the last 6 months
- •Use of luteinizing hormone-releasing hormone (LHRH) agonist androgen suppression (e.g., Lupron, Zoladex), anti-androgen (e.g., Casodex, Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents within the last 6 months
- •Current use of any organic nitrate or as needed nitrates (e.g., use of nitroglycerin)
- •Current use of cimetidine, ketoconazole, itraconazole, erythromycin, or ritonavir
- •Known moderate to severe renal insufficiency or end-stage renal disease
- •Known severe hepatic impairment
- •Use of mechanical (vacuum) devices, intracorporeal, intraurethral, topical, or oral (sildenafil, tadalafil, vardenafil) agents as therapy for ED or supplements to enhance sexual function within 5-7 days prior to the start of RT. Patients who discontinue these therapies remain eligible if they can meet eligibility criteria
- •Pretreatment (before starting prostate cancer treatment) ED as measured by IIEF Question 1, "How often were you able to get an erection during sexual activity?" - with responses of:
- •"no sexual activity" [response 0] or
- •"almost never/never" [response 1] or
- •"a few times (much less than half the time)" [response 2]
- •Prior penile implant or history of bilateral orchiectomy
- •Prior prostatectomy, prostatic cryosurgery or high-intensity focused ultrasound (HIFU), radionuclide prostate brachytherapy, or chemotherapy for prostate cancer
- •Prior or anticipated combined external RT and brachytherapy
- •Prior or anticipated external RT to the pelvic ± para-aortic lymph nodes
- •Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immunocompromised patients.
- •Anatomical genital abnormalities or concurrent conditions that in the estimation of the physician would prohibit sexual intercourse or prevent study completion
- •Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up
研究组 & 干预措施
Tadalafil
Experimental
Tadalafil
干预措施: Tadalafil (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)
时间窗: Baseline and 30 weeks from the start of radiation therapy
EF is measured by Question 1 of the International Index of Erectile Function (IIEF). The IIEF is a validated 15-item for measuring patient-reported erectile function. Question 1 asks "How often were you able to get an erection during sexual activity?" Responses ranged from 0=no sexual activity, to 5=Almost always or always. Higher scores indicated better functioning. All patients have erectile function prior to initiation of RT, indicated by a score of 3, 4, or 5 on IIEF Q1. Patients with a lower IIEF Q1 score at weeks 28-30 than at baseline will have less erectile function and be categorized as nonresponders. Patients with similar or improved erectile function will be categorized as responders (maintaining). Patient-related predictors of at erectile function at this time point are also reported with this outcome measure.
次要结局
- Percentage of Patients Maintaining Spontaneous (Off-drug) EF at Years 1 and 2 After Initiation of RT(Baseline, 1 and 2 years from the start of tadalafil or placebo)
- Overall Patient Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire (SAQ) Score(Baseline, week 30 and years 1 and 2 after the start of treatment)
- Patient Marital Adjustment as Measured by the Locke's Marital Adjustment Test(Baseline, week 30 and years 1 and 2 after the start of treatment)
- Overall Sexual Function as Measured by Change From Baseline in the International Index of Erectile Function (IIEF)(Baseline, week 30, and years 1 and 2 from start of treatment)
- Overall Partner Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire-Partner (SAQ-P) Score(Baseline, week 30 and years 1 and 2 after the start of treatment)
- Partner Marital Adjustment as Measured by the Locke's Marital Adjustment Test(Baseline, week 30 and years 1 and 2 after the start of treatment)
研究者
研究点 (192)
Loading locations...
相似试验
已完成
4 期
A Study of Tadalafil After Radical ProstatectomyErectile DysfunctionNCT01026818Eli Lilly and Company583
已完成
3 期
To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After TakingImpotenceNCT00547508Eli Lilly and Company485
已完成
3 期
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)Benign Prostate HyperplasiaErectile DysfunctionNCT01937871Eli Lilly and Company909
已完成
2 期
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract ProblemsProstatic HyperplasiaProstateNCT00547625Eli Lilly and Company275
已完成
不适用
Sildenafil in Treating Erectile Dysfunction in Patients With Prostate CancerPsychosocial Effects of Cancer and Its TreatmentRadiation ToxicitySexuality and Reproductive IssuesProstate CancerSexual DysfunctionNCT00057759Radiation Therapy Oncology Group115